BTIG Lifts Price Target on Adeptus Biotechnologies to $22 Citing Strong MRD Momentum
BTIG raised its price target on Adeptus Biotechnologies Corp. (NASDAQ:ADPT) to $22.00 from $21.00 and maintained a Buy rating after the company reported robust Minimal Residual Disease (MRD) performance. Adeptus is trading at $16.47 with a $2.51 billion market capitalization and has returned 105.62% over the past year. The firm delivered double-dig…